share_log

Recursion Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.9%),Peter Kolchinsky(5.9%), etc.

Recursion Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.9%),Peter Kolchinsky(5.9%), etc.

Recursion Pharmaceuticals | SC 13G：超过5%持股股东披露文件-RA Capital Management, L.P.(5.9%),Peter Kolchinsky(5.9%)等
美股SEC公告 ·  07/08 16:22
Moomoo AI 已提取核心信息
On June 28, 2024, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed a Schedule 13G with the SEC, disclosing a 5.9% ownership stake in Recursion Pharmaceuticals, Inc. This stake amounts to 15,384,615 shares of Class A Common Stock. The filing indicates that RA Capital Management, L.P. serves as the investment adviser to the RA Capital Healthcare Fund, L.P., and may be deemed a beneficial owner of the securities held by the fund. The shares are reported based on the 260,812,291 shares of Class A Common Stock outstanding as of the closing of Recursion Pharmaceuticals' public offering. The Reporting Persons have disclaimed beneficial ownership of the reported securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was completed on July 8, 2024, and includes a joint filing agreement among the Reporting Persons.
On June 28, 2024, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed a Schedule 13G with the SEC, disclosing a 5.9% ownership stake in Recursion Pharmaceuticals, Inc. This stake amounts to 15,384,615 shares of Class A Common Stock. The filing indicates that RA Capital Management, L.P. serves as the investment adviser to the RA Capital Healthcare Fund, L.P., and may be deemed a beneficial owner of the securities held by the fund. The shares are reported based on the 260,812,291 shares of Class A Common Stock outstanding as of the closing of Recursion Pharmaceuticals' public offering. The Reporting Persons have disclaimed beneficial ownership of the reported securities except for the purpose of determining their obligations under Section 13(d) of the Act. The filing was completed on July 8, 2024, and includes a joint filing agreement among the Reporting Persons.
2024年6月28日，RA资本管理公司以及Peter Kolchinsky、Rajeev Shah和RA Capital Healthcare Fund共同作为报告人，向证券交易委员会（SEC）提交了13G表格，披露其在Recursion Pharmaceuticals公司的5.9%所有权。这一股份相当于普通A类股票的15,384,615股。该申报指示RA资本管理公司作为RA Capital Healthcare Fund的投资顾问，并可能被认定是基金持有的证券的有益所有人。这些股份是根据Recursion Pharmaceuticals公开发行收盘时的260,812,291股普通A类股票报告的。除了为确定其在《证券交易法》第13(d)章下的义务而报告证券持有之外，报告人否认其报告证券的有益所有权。提交已于2024年7月8日完成，并包括报告人之间的联合申报协议。
2024年6月28日，RA资本管理公司以及Peter Kolchinsky、Rajeev Shah和RA Capital Healthcare Fund共同作为报告人，向证券交易委员会（SEC）提交了13G表格，披露其在Recursion Pharmaceuticals公司的5.9%所有权。这一股份相当于普通A类股票的15,384,615股。该申报指示RA资本管理公司作为RA Capital Healthcare Fund的投资顾问，并可能被认定是基金持有的证券的有益所有人。这些股份是根据Recursion Pharmaceuticals公开发行收盘时的260,812,291股普通A类股票报告的。除了为确定其在《证券交易法》第13(d)章下的义务而报告证券持有之外，报告人否认其报告证券的有益所有权。提交已于2024年7月8日完成，并包括报告人之间的联合申报协议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息